koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastična sredstva - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atopic - drugi dermatološki preparati - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
glimegamma 1 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 1 mg / 1 tableta - glimepirid
glimegamma 4 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 4 mg / 1 tableta - glimepirid
glimegamma 2 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 2 mg / 1 tableta - glimepirid
glimegamma 1 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 1 mg / 1 tableta - glimepirid
glimegamma 3 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 3 mg / 1 tableta - glimepirid
glimegamma 6 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 6 mg / 1 tableta - glimepirid
glimegamma 2 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 2 mg / 1 tableta - glimepirid
glimegamma 3 mg tablete
wÖrwag pharma - glimepirid - tableta - glimepirid 3 mg / 1 tableta - glimepirid